FDA permits Teva, Mylan to market generic Celebrex
This article was originally published in Scrip
Executive Summary
The FDA on 30 May confirmed it has given its blessing for Teva Pharmaceutical Industries and Mylan Pharmaceuticals to market generic versions of Pfizer's non-steroidal anti-inflammatory drug (NSAID) COX-2-inhibitor Celebrex (celecoxib) – a drug that had $2.2bn in sales last year.